Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Phlip Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner, ensuring a focus for the company's current prosecution strategy. This arrangement limits the complexity of managing multiple examiner interactions simultaneously.
The company's active prosecution is contained within 1 distinct art unit. This concentration shows that the technical scope of the pending matter is specialized. JONES, DAMERON LEVEST is the busiest examiner for the company, currently overseeing 1 pending office action. As the only examiner with an active matter, JONES, DAMERON LEVEST holds responsibility for the portfolio's current progress.
Practitioners should note that with 1 pending office action assigned to 1 distinct examiner, the prosecution path is direct. The outcome of the company's current efforts relies on the interpretations of JONES, DAMERON LEVEST within that 1 distinct art unit. This environment allows for a targeted approach to addressing any rejections or requirements raised during the examination of the active matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027337 | RADIOLABELED LIGANDS FOR TARGETED PET/SPECT IMAGING AND METHODS OF THEIR USE | JONES, DAMERON LEVEST | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027337 | RADIOLABELED LIGANDS FOR TARGETED PET/SPECT IMAGING AND METHODS OF THEIR USE | JONES, DAMERON LEVEST | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18027337 | RADIOLABELED LIGANDS FOR TARGETED PET/SPECT IMAGING AND METHODS OF THEIR USE | JONES, DAMERON LEVEST | 1618 | §102§103 | Final Rejection | — | Pending | Mar 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPhlip Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dameron Levest Jones has the most, with 1 of Phlip Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
